Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Oriol

Showing results (71-80 of 250) with videos related to

Pageof 25
Sort By:
Haematologica|August 24, 2014
A new prognostic score for AIDS-related lymphomas in the rituximab-eraStefan K Barta, Xiaonan Xue, Dan Wang, et al.
Haematologica|August 30, 2023
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa studyEnrique M Ocio, Yvonne A Efebera, Roman Hájek, et al.
Frontiers in Immunology|March 8, 2024
CD200 genotype is associated with clinical outcome of patients with multiple myelomaYolanda Gonzalez-Montes, Gemma Osca-Gelis, Rocío Rodriguez-Romanos, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 7, 2024
Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 StudyAlbert Oriol, Roman Hájek, Ivan Spicka, et al.
Cytometry. Part B, Clinical Cytometry|November 30, 2022
Optimization of monocyte gating to quantify monocyte subsets for the diagnosis of chronic myelomonocytic leukemiaRebeca Jurado, Maria Huguet, Blanca Xicoy, et al.
European Journal of Haematology|July 24, 2022
Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysisIvan Spicka, Philippe Moreau, Thomas G Martin, et al.
Cancer Medicine|September 21, 2022
Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myelomaMaría Victoria Mateos, Felipe Prosper, Jesús Martin Sánchez, et al.
Medicina Clinica|January 24, 2006
[Prognostic influence of immunological subtypes of T-cell acute lymphoblastic leukemia. Study of 81 patients]Blanca Xicoy, Josep M Ribera, Albert Oriol, et al.
The Lancet. Oncology|August 28, 2017
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trialMeletios A Dimopoulos, Hartmut Goldschmidt, Ruben Niesvizky, et al.
Haematologica|October 3, 2009
Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trialJosep-Maria Ribera, Albert Oriol, Marcos González, et al.
Pageof 25

Showing results (71-80 of 250) with videos related to

Sort By:
Pageof 25
Haematologica|August 24, 2014
A new prognostic score for AIDS-related lymphomas in the rituximab-eraStefan K Barta, Xiaonan Xue, Dan Wang, et al.
Haematologica|August 30, 2023
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa studyEnrique M Ocio, Yvonne A Efebera, Roman Hájek, et al.
Frontiers in Immunology|March 8, 2024
CD200 genotype is associated with clinical outcome of patients with multiple myelomaYolanda Gonzalez-Montes, Gemma Osca-Gelis, Rocío Rodriguez-Romanos, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 7, 2024
Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 StudyAlbert Oriol, Roman Hájek, Ivan Spicka, et al.
Cytometry. Part B, Clinical Cytometry|November 30, 2022
Optimization of monocyte gating to quantify monocyte subsets for the diagnosis of chronic myelomonocytic leukemiaRebeca Jurado, Maria Huguet, Blanca Xicoy, et al.
European Journal of Haematology|July 24, 2022
Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysisIvan Spicka, Philippe Moreau, Thomas G Martin, et al.
Cancer Medicine|September 21, 2022
Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myelomaMaría Victoria Mateos, Felipe Prosper, Jesús Martin Sánchez, et al.
Medicina Clinica|January 24, 2006
[Prognostic influence of immunological subtypes of T-cell acute lymphoblastic leukemia. Study of 81 patients]Blanca Xicoy, Josep M Ribera, Albert Oriol, et al.
The Lancet. Oncology|August 28, 2017
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trialMeletios A Dimopoulos, Hartmut Goldschmidt, Ruben Niesvizky, et al.
Haematologica|October 3, 2009
Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trialJosep-Maria Ribera, Albert Oriol, Marcos González, et al.
Pageof 25